When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

QR Code

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

Norman J KachuckUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USAAbstract: New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a physician respond to a patient&amp...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Kachuck NJ
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/be798b95f75e4e0ba2267b0d1476072e
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
par: Kimberley Allen-Philbey, et autres
Publié: (2021)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
par: Kerstin Hellwig, et autres
Publié: (2021)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
par: Afsaneh Shirani, et autres
Publié: (2021)

Prevalence of Pediatric Onset Multiple Sclerosis in Saudi Arabia
par: Reem Bunyan, et autres
Publié: (2021)

A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective
par: Alexander Walter, et autres
Publié: (2021)

Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?
par: Sabrina Schr&ouml;der, et autres
Publié: (2011)

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets
par: Christoph Grothe, et autres
Publié: (2021)

The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results
par: Sandra Thiel, et autres
Publié: (2021)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
par: Hayes KC
Publié: (2011)

Attention deficits in Japanese multiple sclerosis patients with minor brain lesion loads
par: Takeda A, et autres
Publié: (2011)

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option
par: Robert W Motl, et autres
Publié: (2010)

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis
par: Aliza Bitton Ben-Zacharia, et autres
Publié: (2021)

The hospital anxiety and depression scale, in patients with multiple sclerosis
par: Pais-Ribeiro JL, et autres
Publié: (2018)

Cognitive dysfunction in pediatric multiple sclerosis
par: Suppiej A, et autres
Publié: (2014)

The Multiple Sclerosis Treatment Optimization Program
par: Annette Langer‐Gould, et autres
Publié: (2021)

Cognitive status in patients with multiple sclerosis in Lanzarote
par: Pérez-Martín MY, et autres
Publié: (2016)

Psychiatrists’ Understanding and Management of Conversion Disorder: A Bi-National Survey and Comparison with Neurologists
par: Dent B, et autres
Publié: (2020)

Neurobehavioral burden of multiple sclerosis with nanotheranostics
par: Sriramoju B, et autres
Publié: (2015)

Role of oral teriflunomide in the management of multiple sclerosis
par: Tanasescu R, et autres
Publié: (2013)

Cannabinoids in the management of spasticity associated with multiple sclerosis
par: Anna Maria Malfitano, et autres
Publié: (2008)

Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature
par: Hsieh PC, et autres
Publié: (2013)

Impact of Andropause on Multiple Sclerosis
par: Maria C. Ysrraelit, et autres
Publié: (2021)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
par: Warnke C, et autres
Publié: (2011)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
par: Clemens Warnke, et autres
Publié: (2009)

The role of glatiramer acetate in the early treatment of multiple sclerosis
par: David W Brandes
Publié: (2010)

Association between smoking and cognitive impairment in multiple sclerosis
par: Özcan ME, et autres
Publié: (2014)

Gut microbiome is associated with multiple sclerosis activity in children
par: Mary K. Horton, et autres
Publié: (2021)

Neuropsychiatric assessments in patients with multiple sclerosis in early phases and with low disability
par: Schmidt SL, et autres
Publié: (2018)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
par: Lugaresi A, et autres
Publié: (2013)

Measuring treatment response to advance precision medicine for multiple sclerosis
par: Peter A. Calabresi, et autres
Publié: (2021)

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
par: Introna A, et autres
Publié: (2018)

Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report
par: De Pasquale C, et autres
Publié: (2014)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
par: Dubey D, et autres
Publié: (2015)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
par: Castrop F, et autres
Publié: (2013)

Disease-modifying therapies in relapsing&ndash;remitting multiple sclerosis
par: Fabricio Gonz&aacute;lez-Andrade, et autres
Publié: (2010)

Efficacy of a short cognitive training program in patients with multiple sclerosis
par: Pérez-Martín MY, et autres
Publié: (2017)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
par: Babij R, et autres
Publié: (2015)

Pareidolia in Parkinson’s Disease and Multiple System Atrophy
par: Kentaro Kurumada, et autres
Publié: (2021)

A study of patients with aggressive multiple sclerosis at disease onset
par: Kaunzner UW, et autres
Publié: (2016)

Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
par: Julie A Murphy, et autres
Publié: (2010)